Effects of dietary conjugated linoleic acid on serum visfatin level and tumor number and size in rat model of colorectal cancer

authors:

avatar Zahra kamal , avatar Marjan Ajami , avatar Nasrin Beheshti , avatar Morteza Abdollahi , avatar Sayed Hosein Davoodi ORCID , *

Koomesh: Vol.18, issue 1; 165-173
published online: September 28, 2016
article type: issue_documents_importer
received: February 01, 2016
accepted: July 02, 2016

how to cite: kamal Z, Ajami M, Beheshti N, Abdollahi M, Davoodi S H. Effects of dietary conjugated linoleic acid on serum visfatin level and tumor number and size in rat model of colorectal cancer. koomesh. 2016;18(1):e151159. 

Abstract

Introduction: Colorectal cancer is the third causes of cancer death in the world. Recent studies have shown that the serum levels of visfatin are increased during malignancies, suugesting a role for vistatin in pathogenegis of malignancies. It is suggested that conjugated linoleic acid, (CLA) can reduce the serum levels of vistatin. The aim of this syudy was to study the effects of dietary conjugated linoleic acid on serum visfatin level in rat model of colorectal cancer. Materials and Methods: Sixteen male Wistar rats, weighing 250-300 g were divided into two groups: control and experimental. Both groups were injected subcutaneously, with 1,2- Dimethyl Hydrazine at a dose of 15 mg/kg of body weight, twice per week for 6 weeks. The control group and experimental groups were gavaged with water (2 ml/kg) and CLA (200 mg/kg), respectively, for the first 4 weeks of study. After 6 weeks, the rats were killed and their blood and colorectal tissues were collected in order to analyze serum visfatin, tumor number and tumor size respectively by ELISA method, tumor numbering and macroscopic analysing. Results: Visfatin levels decreased dramatically in the experimental group than control group (P=0.001). Tumor number and tumor size increased considerably in the control group than experimental group (P = 0.000). There was a positive correlation between visfatin levels with tumor number (r =0.701, p = 0.001) and also between plasma visfatin with tumor number×tumor size (r=0.771, p=0.000). Conclusion: This study shows that dietary CLA by reducing serum visfatin can decrease the tumor number and tumor size in rat model of colorectal cancer.  Thus, CLA suppresses colon carcinogenesis by a mechanim probably involving reduced serum visfatin

References

  • 1.

    Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, Dastgiri S. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health 2015; 15: 997.

  • 2.

    Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev 2005; 6: 130-134.

  • 3.

    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J. Jemal A Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87.

  • 4.

    Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S. Colorectal cancer in iran: molecular epidemiology and screening strategies. J Cancer Epidemiol 2015; 2015: 64302.

  • 5.

    Malekzadeh R, Bishehsari F, Mahdavinia M, Ansari R. Epidemiology and molecular genetics of colorectal cancer in Iran: A Review. Arch Iranian Med 2009; 12: 161-169.

  • 6.

    Rezaianzadeh A, Safarpour AR, Marzban M, Mohagheg A. A systematic review over the incidence of colorectal cancer in Iran. Ann Colorectal Res 2015; 3: e25724.

  • 7.

    Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev 2005; 6: 130-134.

  • 8.

    Safaee A, Moghimi-Dehkordi B, Fatemi SR, Pourhoseingholi MA, Vahedi M, Pourhoseingholi A, et al. Frequency of colorectal cancer in healthy individual's relatives: A cross-sectional population-based study, Koomesh 2011; 12: 129-133. (Persian).

  • 9.

    Norat T, Riboli E. Dairy products and colorectal cancer, A review of possible mechanisms and epidemiological evidence. Eur J Clin Nutr 2003; 57: 1-17.

  • 10.

    Larsson SC, Bergkvist L, Wolk A. High-fat dairy food and conjugated linoleic acid intakes in relation to colorectal cancer incidence in the Swedish Mammography Cohort. Am J Clin Nutr 2005; 82: 894-900.

  • 11.

    Clement Ip, Sou Fei Chin, Joseph A, Scimeca, Michael W, Pariza. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991; 6118-6124.

  • 12.

    Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, Colditz GA, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004; 96: 1015-1022.

  • 13.

    Chouinard PY, Corneau L, Butler WR, Chilliard Y, Drackley JK, Bauman DE. Effect of dietary lipid source on conjugated linoleic acid concentrations in milk fat. J Dairy Sci 2001; 84: 680-690.

  • 14.

    Kelley NS, Hubbard NE, Erickson KL, Conjugated linoleic acid isomers and cancer. J Nutr 2007; 137: 2599-2607.

  • 15.

    Park HS, Ryu JH, Ha YL, Park JH. Dietary conjugated linoleic acid (CLA) induces apoptosis of colonic mucosa in 1,2-dimethylhydrazine-treated rats: a possible mechanism of the anticarcinogenic effect by CLA. Br J Nutr 2007; 86: 549.

  • 16.

    Wahle KW, Heys SD, Rotondo D. Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 2004; 43: 553-587.

  • 17.

    Palombo JD, Ganguly A, Bistrian BR, Menard MP. The antiproliferative effects of biologically active isomers of conjugated linoleic acid on human colorectal and prostatic cancer cells. Cancer Lett 2002; 177: 163-172.

  • 18.

    Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr 2010; 140: 515-521.

  • 19.

    Kim KH, Park HS. Dietary supplementation of conjugated linoleic acid reduces colon tumor incidence in DMH-treated rats by increasing apoptosis with modulation of biomarkers. Nutrition 2003; 19: 772-777.

  • 20.

    Mandir N, Goodlad RA. Conjugated linoleic acids differentially alter polyp number and diameter in the Apc(min/+) mouse model of intestinal cancer. Cell Prolif 2008; 41: 279-291.

  • 21.

    Soel SM, Choi OS, Bang MH, Yoon Park JH, Kim WK. Influence of conjugated linoleic acid isomers on the metastasis of colon cancer cells in vitro and in vivo. J Nutr Biochem 2007; 18: 650-657.

  • 22.

    Guidong H, Xianfeng Zh, Yusheng C, Yan Ch. Antiproliferative effects of conjugated linoleic acid on human colon adenocarcinoma cell line Caco-2. Asia Pac J Clin Nutr 2007; 16: 432-436.

  • 23.

    Shiraishi R, Iwakiri R, Fujise T, Kuroki T, Kakimoto T, Takashima T, et al. Conjugated linoleic acid suppresses colon carcinogenesis in azoxymethane-pretreated rats with long-term feeding of diet containing beef tallow. J Gastroenterology 2010; 45: 625-635.

  • 24.

    Baghi AN, Mazani M, Nemati A, Amani M, Alamolhoda S, Mogadam RA. Anti-inflammatory effects of conjugated linoleic acid on young athletic males. J Pak Med Assoc 2016; 66: 280-284.

  • 25.

    Bassaganya-Riera J, Hontecillas R, Beitz DC. Colonic anti-inflammatory mechanisms of conjugated linoleic acid. Clin Nutr 2002; 21: 451-459.

  • 26.

    Ghaemmaghami S, Mohaddes SM, Hedayati M, Gorgian Mohammadi M, et al. Resistin and visfatin expression in HCT-116 colorectal cancer cell line. IJMCM Summer 2013; 2. (Persian).

  • 27.

    Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010; 101: 1286-1291.

  • 28.

    Chen M, Wang Y, Li Y, Zhao L, Ye S, Wang S, et al. Association of plasma visfatin with risk of colorectal cancer: An observational study of Chinese patients. Asia Pac J Clin Oncol 2016; 12: e65-74.

  • 29.

    Huang WS, Chen CN, Sze CI, Teng CC. Visfatin induces stromal cell-derived factor-1 expression by beta1 integrin signaling in colorectal cancer cells. J Cell Physiol 2013; 228: 1017-1024.

  • 30.

    Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine 2013; 62: 81-85.

  • 31.

    Buldak RJ, Gowarzewski M, Buldak L, Skonieczna M, et al, viability and oxidative response of human colorectal HCT-116 cancer cells treated with visfatin/ENAMPT in vitro. J Phys Pharmacol 2015; 66: 557-566.

  • 32.

    Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 285-291.

  • 33.

    Lu GW, Wang QJ, Xia MM, Qian J. Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients. Peptides 2014; 58: 60-64.

  • 34.

    Neubauer K, Misa IB, Diakowska D, Kapturkiewicz B, Gamian A, Krzystek-Korpacka M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1beta, and anemia. BioMed Res Int 2015; 2015: 523930.

  • 35.

    Lv X, Zhang L, Zhu Y, Said HM, Shi J, Xu G. Regulative effect of nampt on tumor progression and cell viability in human colorectal cancer. J Cancer 2015; 6: 849-858.

  • 36.

    Pilz S, Mangge H, Obermayer-Pietsch B, Marz W. Visfatin/pre-B-cell colony-enhancing factor: A protein with various suggested functions. J Endocrinol Invest 2007; 30: 138-144.

  • 37.

    Huang WS, Chen CN, Sze CI, Teng CC. Visfatin induces stromal cell-derived factor-1 expression by beta1 integrin signaling in colorectal cancer cells. J Cell Physiol 2013; 228: 1017-1024.

  • 38.

    Pittelli M, Cavone L, Lapucci A, Oteri C, Felici R, Niccolai E, et al. Nicotinamidephospho- ribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes. Immunol Cell Biol 2014; 92: 191-199.

  • 39.

    Imai SI. Nicotinamidephosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009; 15: 20-28.

  • 40.

    Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-369.

  • 41.

    Dep Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med 2011; 21: 264-275.

  • 42.

    Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-1506.

  • 43.

    Saghebjoo M, Dastigerdi S, Afzalpour ME, Hedayati M. Effects of aerobic and resistance training on plasma visfatin levels in overweight women. Koomesh 2012; 13: 225-232. (Persian).

  • 44.

    Park HS, Ryu JH, Ha YL, Park JH. Dietary conjugated linoleic acid (CLA) induces apoptosis of colonic mucosa in 1,2-dimethylhydrazine-treated rats: a possible mechanism of the anticarcinogenic effect by CLA. Br J Nutr 2007; 86: 549.

  • 45.

    Sanders S, Teachey M, Ptock A, Kraemer K, Hasselwander O, Henriksen EJ, Baumgard LH. Effects of specific conjugated linoleic acid isomers on growth characteristics in obese Zucker rats. Lipids 2004; 39: 537-543.

  • 46.

    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.

  • 47.

    Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 1998; 3: 69-78.

  • 48.

    Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659: 15-30.

  • 49.

    Wang K, Karin M. Tumor-Elicited inflammation and colorectal cancer. Adv Cancer Res 2015; 128: 173-196.

  • 50.

    Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer 2013; 4: 447-456.

  • 51.

    Hajianfar H, Hosseinzadeh MJ, Bahonar A, Mohammad K, Askari GR, Entezari MH, et al. The effect of omega-3 on the serum visfatin concentration in patients with type II diabetes. J Res Med Sci 2011; 16: 490-495.

  • 52.

    Rafraf M, Mohammadi E, Asghari-jafarabadi M, Farzadi L. Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome. J Am Coll Nutr 2012; 31: 361-368##.